What Is OSNA?

OSNA – the new generation of sentinel lymph node analysis in breast cancer.

Sentinel node biopsy has rapidly emerged as the surgical procedure of choice for early stage, clinically node-negative breast cancer patients. Conventional intra-operative analysis of the sentinel lymph node (SLN) has, until now, been performed by frozen section or touch imprint with a rapid H&E (haematoxylin and eosin) staining. The sensitivity of these histopathological methods is low because only a small proportion of the lymph node tissue can be investigated in an intra-operative setting. As a result, there is a considerable risk of false-negative results which may only be identified by subsequent postoperative examination.

OSNA (One Step Nucleic Acid Amplification) is a new and widely established diagnostic approach which, for the first time, enables analysis of the whole lymph node in an intra-operative timeframe. A final, fully informed, clinical decision can be taken with confidence, without the requirement for a second surgical procedure or a confirmatory histopathological analysis.

What is OSNA?What is the fund about?How can I help?